163 related articles for article (PubMed ID: 21645463)
1. [Gemcitabine in RRM1-negative advanced refractory non-small cell lung cancer (NSCLC): a case report].
Zhao M; Yang H; He J
Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):550-3. PubMed ID: 21645463
[No Abstract] [Full Text] [Related]
2. [Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients].
Gao Z; Han B; Shen J; Gu A; Zhong H
Zhongguo Fei Ai Za Zhi; 2011 Apr; 14(4):340-4. PubMed ID: 21496433
[TBL] [Abstract][Full Text] [Related]
3. Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
Dong X; Hao Y; Wei Y; Yin Q; Du J; Zhao X
PLoS One; 2014; 9(3):e92320. PubMed ID: 24647522
[TBL] [Abstract][Full Text] [Related]
4. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis.
Gong W; Zhang X; Wu J; Chen L; Li L; Sun J; Lv Y; Wei X; Du Y; Jin H; Dong J
Lung Cancer; 2012 Mar; 75(3):374-80. PubMed ID: 21889227
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer.
Zhang Q; Zhu X; Zhang L; Sun S; Huang J; Lin Y
Cancer Chemother Pharmacol; 2014 Oct; 74(4):839-46. PubMed ID: 25119181
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.
Reynolds C; Obasaju C; Schell MJ; Li X; Zheng Z; Boulware D; Caton JR; Demarco LC; O'Rourke MA; Shaw Wright G; Boehm KA; Asmar L; Bromund J; Peng G; Monberg MJ; Bepler G
J Clin Oncol; 2009 Dec; 27(34):5808-15. PubMed ID: 19884554
[TBL] [Abstract][Full Text] [Related]
7. Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin.
Qiu ZQ; Zhao K
Asian Pac J Cancer Prev; 2014; 15(17):7303-7. PubMed ID: 25227833
[TBL] [Abstract][Full Text] [Related]
8. The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
Nie X; Cheng G; Ai B; Zhang S
Cancer Biomark; 2013 Jan; 13(6):433-40. PubMed ID: 24595080
[TBL] [Abstract][Full Text] [Related]
9. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Boukovinas I; Papadaki C; Mendez P; Taron M; Mavroudis D; Koutsopoulos A; Sanchez-Ronco M; Sanchez JJ; Trypaki M; Staphopoulos E; Georgoulias V; Rosell R; Souglakos J
PLoS One; 2008; 3(11):e3695. PubMed ID: 19002265
[TBL] [Abstract][Full Text] [Related]
10. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
Shimizu J; Horio Y; Osada H; Hida T; Hasegawa Y; Shimokata K; Takahashi T; Sekido Y; Yatabe Y
Respirology; 2008 Jun; 13(4):510-7. PubMed ID: 18494946
[TBL] [Abstract][Full Text] [Related]
11. The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.
Mlak R; Krawczyk P; Ciesielka M; Kozioł P; Homa I; Powrózek T; Prendecka M; Milanowski J; Małecka-Massalska T
Clin Transl Oncol; 2016 Sep; 18(9):915-24. PubMed ID: 26650486
[TBL] [Abstract][Full Text] [Related]
12. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
Liu XQ; Wang WX; Lin L; Song ST
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
[TBL] [Abstract][Full Text] [Related]
13. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
[TBL] [Abstract][Full Text] [Related]
14. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
Davidson JD; Ma L; Flagella M; Geeganage S; Gelbert LM; Slapak CA
Cancer Res; 2004 Jun; 64(11):3761-6. PubMed ID: 15172981
[TBL] [Abstract][Full Text] [Related]
15. RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients--a short report.
Zeng C; Fan W; Zhang X
Cell Oncol (Dordr); 2015 Aug; 38(4):319-25. PubMed ID: 26092210
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between the efficacy of gemcitabine/cisplatin adjuvant chemotherapy and RRM1 protein expression in postoperative NSCLC patients].
Ma K; Li E; Guo Y; Wang X; Sun H; Shao G
Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):505-10. PubMed ID: 25327655
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
[TBL] [Abstract][Full Text] [Related]
18. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Rosell R; Danenberg KD; Alberola V; Bepler G; Sanchez JJ; Camps C; Provencio M; Isla D; Taron M; Diz P; Artal A;
Clin Cancer Res; 2004 Feb; 10(4):1318-25. PubMed ID: 14977831
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
Kim SO; Jeong JY; Kim MR; Cho HJ; Ju JY; Kwon YS; Oh IJ; Kim KS; Kim YI; Lim SC; Kim YC
Clin Cancer Res; 2008 May; 14(10):3083-8. PubMed ID: 18483375
[TBL] [Abstract][Full Text] [Related]
20. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]